ArticleInsights into imaging2025
Renal angiomyolipoma-investigating radiological signs indicative of risk for bleeding.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complicated renal angiomyolipoma with renal vein fat embolism mimicking lipid-rich renal cell carcinoma: A case report.Radiology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo compare imaging differences between bleeding and non-bleeding angiomyolipoma with respect to the proportion and attenuation of the angiomyogenic component and the occurrence and size of aneurysms. MATERIALS AND
methodsCT scans and angiographies preceding 58 consecutive embolisations at two institutions from 1999 to 2018 were analysed retrospectively. Tumour volume was measured by contouring the angiomyolipoma on CT scans. The partial volume of the angiomyogenic component (blood vessels and smooth muscle relative to fatty tissue) was derived using attenuation threshold values measured in Hounsfield Units.
resultsBleeding angiomyolipoma exhibited a significantly higher proportion of angiomyogenic component (23%) than non-bleeding angiomyolipoma (8%) (p = 0.042). Angiomyolipoma with 0-5% angiomyogenic component had a lower risk of bleeding compared to those with ≥ 5% angiomyogenic component (13% vs 42%). Mean attenuation values of angiomyogenic components did not differ between bleeders and non-bleeders. Aneurysms were observed in 24% of angiomyolipoma during angiography. No statistically significant association was found between the occurrence of aneurysms and bleeding, neither when all aneurysms were included nor when only aneurysms ≥ 5 mm were considered. Tuberous sclerosis patients had larger tumours (11.4 cm vs 6.0 cm), but no significant difference in bleeding was observed (p = 0.53).
conclusionsA higher proportion of the angiomyogenic component in bleeding renal angiomyolipoma suggests a possible association with bleeding. Angiomyolipoma with less than 5% angiomyogenic components may represent a subgroup with a reduced risk of bleeding. Our findings do not confirm the widely accepted assumption that aneurysms significantly increase the risk of bleeding. CRITICAL RELEVANCE STATEMENT: Measuring the angiomyogenic component in renal angiomyolipoma could help address current knowledge gaps and aid in the more efficient selection of patients for therapeutic interventions. KEY POINTS: Identifying risk factors for bleeding beyond tumour size is important. Very low angiomyogenic component tumours may have reduced bleeding risk. The presence of aneurysms may not significantly increase bleeding risk. Reporting angiomyogenic proportion on CT may aid in treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.